News | August 10, 2025
Aurobindo Pharma Q1 FY26 PAT slips 10% YoY to Rs. 824 Cr
Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore
Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore
With this addition, the company’s total Installed MCC Capacity will rise to 30,000 MTPA
These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs
Fermenta now becomes one of the only two companies globally to hold a CEP for this variant of Vitamin D3
The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs
The company received one observation in the Form-483
Shelcal Total marks the brand’s evolution into a modern, consumer-focused nutrition portfolio
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
Phosphate-based excipients provide higher bulk densities and enable the reduction of the tablet sizes
Subscribe To Our Newsletter & Stay Updated
